All I said was it will replace SoC and that's where the commercial valuation is for Azer-Cel as it's logical, I didn't mentioned when or immediate and said why wouldn't clinician decide to use Azer-Cel as the first line of treatment given how the clinical trial was designed. I'm sure BP will have more resource to make this happen much quicker.
So you don't think it's very low risk Azer-Cel will be a SoC before Autologous CAR T given how the clinical trial was design and the low manufacturing cost making this CAR T treatment more affordable to DLBCL patient worldwide and not just in 1st world countries?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)